David R. M. Jansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David R. M. Jansen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
(on behalf of the education working group of the Dutch Society for Clinical Pharmacology
1 shared publicationBiopharmacy)
1 shared publicationCarolina J. P. W Keijsers
Department of Geriatric Medicine, Jeroen Bosch Hospital, Den Bosch, The Netherlands
1 shared publicationCornelis Kramers
Department of Pharmacology and Toxicology and Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
1 shared publication- Corrie E. Erasmus
Department of Pediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center Amalia Children's Hospital, Nijmegen, the Netherlands
1 shared publication D. S. Everaerd
Department of Psychiatry Radboudumc Nijmegen The Netherlands
1 shared publication
Latest Publications
- Open Access
- 8 June 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (10) , 1083-1087
Potential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms
Objective: Lower urinary tract symptoms (LUTS) are becoming more prevalent in the ageing population of males living with HIV. Drugs to treat LUTS are known for both their potential role as victims in drug–drug interactions (DDIs) and their side effects. We aimed to evaluate the current use of drugs to treat LUTS and to assess potential DDIs in our cohort of adult males living with HIV.Design: This was a retrospective review of pharmacy records.Methods: We recorded the combination antiretroviral therapy (cART) regimen and any use of drugs to treat LUTS (anatomical therapeutic chemical codes G04CA/CB/CX and G04BD). Potential DDIs were assessed using the interaction checker developed by the University of Liverpool (https://www.hiv-druginteractions.org/checker).Results: A total of 411 adult males living with HIV were included in this analysis. The median (interquartile range [IQR]) age was 53 (41–62) years. Nineteen (4.6%) patients used one or more drugs to treat LUTS. As expected, older patients were more likely to be receiving treatment for LUTS: Q1 (20–40 years) = 0%; Q2 (41–52 years) = 2%; Q3 (53–61 years) = 7%; Q4 (62–79 years) = 10%. Seven potential DDIs between cART and LUTS treatment were noted in six of the 19 (32%) patients. Following medication reviews of these six patients, the following interventions were proposed: evaluate safe use of alpha‐blocker (n = 4), change in cART (n = 2), and dose reduction of the anticholinergic agent (n = 1).Conclusion: Treatment for LUTS coincided with cART in 7%–10% of patients aged above the median age of 53 years in our cohort. Improvements in DDI management appeared to be possible in this growing cohort of males living with HIV and with LUTS.
- 8 June 2023
- Published by Wiley in HIV Medicine
- Vol. 24 (10) , 1083-1087
Open AccessPotential drug–drug interactions in males living with HIV who use drugs to treat lower urinary tract symptoms
Objective: Lower urinary tract symptoms (LUTS) are becoming more prevalent in the ageing population of males living with HIV. Drugs to treat LUTS are known for both their potential role as victims in drug–drug interactions (DDIs) and their side effects. We aimed to evaluate the current use of drugs to treat LUTS and to assess potential DDIs in our cohort of adult males living with HIV.Design: This was a retrospective review of pharmacy records.Methods: We recorded the combination antiretroviral therapy (cART) regimen and any use of drugs to treat LUTS (anatomical therapeutic chemical codes G04CA/CB/CX and G04BD). Potential DDIs were assessed using the interaction checker developed by the University of Liverpool (https://www.hiv-druginteractions.org/checker).Results: A total of 411 adult males living with HIV were included in this analysis. The median (interquartile range [IQR]) age was 53 (41–62) years. Nineteen (4.6%) patients used one or more drugs to treat LUTS. As expected, older patients were more likely to be receiving treatment for LUTS: Q1 (20–40 years) = 0%; Q2 (41–52 years) = 2%; Q3 (53–61 years) = 7%; Q4 (62–79 years) = 10%. Seven potential DDIs between cART and LUTS treatment were noted in six of the 19 (32%) patients. Following medication reviews of these six patients, the following interventions were proposed: evaluate safe use of alpha‐blocker (n = 4), change in cART (n = 2), and dose reduction of the anticholinergic agent (n = 1).Conclusion: Treatment for LUTS coincided with cART in 7%–10% of patients aged above the median age of 53 years in our cohort. Improvements in DDI management appeared to be possible in this growing cohort of males living with HIV and with LUTS.
- Open Access
- 25 September 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (2) , 647-659
The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers
Background and purpose: Rhabdomyolysis is a medical emergency characterized by acute skeletal muscle breakdown with a sudden rise and subsequent fall of serum creatine kinase (CK) levels. Rhabdomyolysis events are provoked by exposure to external triggers, possibly in combination with an increased genetic susceptibility. We aimed to describe comprehensively the external triggers and potentially pathogenic genetic variants possibly implicated in increased rhabdomyolysis susceptibility.Methods: We performed a retrospective single‐center study, including a total of 1302 patients with an acute CK level exceeding 2000 IU/l.Results: Anoxia was the most frequently reported trigger (40%). A subset of 193 patients were clinically suspected of an underlying genetic disorder (recurrent episodes, a positive family history, very high or persistently increased CK levels). In 72 of these patients, an unequivocal genetic defect was identified. A total of 22 genes with pathogenic variants were identified, including 52 different variants. Of those, 11 genes have been previously associated with rhabdomyolysis (ACADVL, ANO5, CPT2, DMD, DYSF, FKRP, HADHA, PGM1, LPIN1, PYGM, RYR1). Eleven genes are probably implicated in increased susceptibility (including AGL, CAPN3, CNBP, DMPK, MAGT1, ACADM, SCN4A, SGCA, SGCG, SMPD1, TANGO2).Conclusion: These findings suggest that the spectrum of genetic susceptibility for rhabdomyolysis has not yet been completely clarified. With the increasing availability of next‐generation sequencing in a diagnostic setting, we expect that in more cases a genetic defect will be identified.
- 25 September 2020
- Published by Wiley in European Journal of Neurology
- Vol. 28 (2) , 647-659
Open AccessThe etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers
Background and purpose: Rhabdomyolysis is a medical emergency characterized by acute skeletal muscle breakdown with a sudden rise and subsequent fall of serum creatine kinase (CK) levels. Rhabdomyolysis events are provoked by exposure to external triggers, possibly in combination with an increased genetic susceptibility. We aimed to describe comprehensively the external triggers and potentially pathogenic genetic variants possibly implicated in increased rhabdomyolysis susceptibility.Methods: We performed a retrospective single‐center study, including a total of 1302 patients with an acute CK level exceeding 2000 IU/l.Results: Anoxia was the most frequently reported trigger (40%). A subset of 193 patients were clinically suspected of an underlying genetic disorder (recurrent episodes, a positive family history, very high or persistently increased CK levels). In 72 of these patients, an unequivocal genetic defect was identified. A total of 22 genes with pathogenic variants were identified, including 52 different variants. Of those, 11 genes have been previously associated with rhabdomyolysis (ACADVL, ANO5, CPT2, DMD, DYSF, FKRP, HADHA, PGM1, LPIN1, PYGM, RYR1). Eleven genes are probably implicated in increased susceptibility (including AGL, CAPN3, CNBP, DMPK, MAGT1, ACADM, SCN4A, SGCA, SGCG, SMPD1, TANGO2).Conclusion: These findings suggest that the spectrum of genetic susceptibility for rhabdomyolysis has not yet been completely clarified. With the increasing availability of next‐generation sequencing in a diagnostic setting, we expect that in more cases a genetic defect will be identified.
- Open Access
- 18 May 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 75 (9) , 1261-1268
Towards a “prescribing license” for medical students: development and quality evaluation of an assessment for safe prescribing
This report describes the development and validation process of an assessment with national consensus in appropriate and safe pharmacotherapy.
- 18 May 2019
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 75 (9) , 1261-1268
Open AccessTowards a “prescribing license” for medical students: development and quality evaluation of an assessment for safe prescribing
This report describes the development and validation process of an assessment with national consensus in appropriate and safe pharmacotherapy.